AbbVie Partners With Iambic on AI Small Molecule Discovery
AbbVie and Iambic announced a multi year collaboration on 21 September 2026 to apply Iambic's Enchant v3 AI platform across immunology, neuroscience, and oncology small molecule programs.
What changed
AbbVie and Iambic announced on 21 September 2026 a multi year collaboration to accelerate discovery and development of small molecule therapies with first in class and best in class potential across immunology, neuroscience, and oncology. The companies will apply Iambic's molecular superintelligence platform, including its Enchant v3 model trained on more than 6,000 molecular properties.
Nicholas Donoghoe, M.D., AbbVie executive vice president and chief business and strategy officer, framed the deal as equipping discovery scientists with purpose built AI rather than generic tooling. Iambic remains a clinical stage company developing its own pipeline while licensing platform capabilities to partners.
Why it matters
Big pharma AI partnerships are shifting from exploratory pilots to multi year discovery integrations with named therapeutic areas. AbbVie's immunology and oncology franchises make this a high stakes test of whether AI platforms can compress hit identification timelines without sacrificing medicinal chemistry rigor. For biotech investors, Iambic gains validation from a top tier partner beyond its internal pipeline.
Who is affected
Medicinal chemistry leaders at large pharma, AI drug discovery vendors competing on property prediction breadth, and BD teams benchmarking platform deal structures. Competing labs such as Recursion, Insilico, and Exscientia will face questions on how Enchant v3's property count compares to their published models.
What to do next
If your discovery organization lacks a named AI platform partner, use the AbbVie Iambic scope as a template: require therapeutic area specificity, property coverage disclosure, and joint program milestones before signing a multi year license.
What to watch
The first AbbVie program advanced with Iambic assistance that reaches a public milestone, and whether either party publishes quantitative hit rate or cycle time improvements attributable to the platform.
Tom Miller, Ph.D., Iambic co founder and CEO, said the partnership aims to address unmet patient need by combining Iambic's platform with AbbVie's therapeutic area expertise. AbbVie's Donoghoe emphasized that fit for purpose AI could expand what is possible in R&D and accelerate the company's commitment to patient impact.
Sources
- Primary. Iambic, AbbVie and Iambic Announce Collaboration to Accelerate AI driven Drug Discovery (21 September 2026). Establishes therapeutic areas, Enchant v3 reference, property count, and executive quotes.